Home Cart Sign in  
Chemical Structure| 14371-10-9 Chemical Structure| 14371-10-9

Structure of trans-Cinnamaldehyde
CAS No.: 14371-10-9

Chemical Structure| 14371-10-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Trans-Cinnamaldehyde is a natural product isolated from cinnamon essential oil, role as a hypoglycemic agent, a phenylalanine ammonia-lyase inhibitor, a vasodilator agent, an antifungal agent, a flavouring agent, a plant metabolite and a sensitiser.

Synonyms: Cinnamaldehyde

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of trans-Cinnamaldehyde

CAS No. :14371-10-9
Formula : C9H8O
M.W : 132.16
SMILES Code : O=C/C=C/C1=CC=CC=C1
Synonyms :
Cinnamaldehyde
MDL No. :MFCD00007000
InChI Key :KJPRLNWUNMBNBZ-QPJJXVBHSA-N
Pubchem ID :637511

Safety of trans-Cinnamaldehyde

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H317-H319-H335
Precautionary Statements:P261-P280-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Rat intestinal epithelial cells (IEC-6) 325, 560, 750 μM 1 hour (adhesion assay), 3 hours (invasion assay) To evaluate the effect of trans-cinnamaldehyde on C. sakazakii adhesion and invasion of IEC-6 cells. Results showed that 560 and 750 μM TC significantly inhibited adhesion (reduced by 35% and 47%, respectively) and invasion (750 μM completely inhibited invasion). PMC4057751
Human embryonic intestinal cells (INT-407) 325, 560, 750 μM 1 hour (adhesion assay), 3 hours (invasion assay) To evaluate the effect of trans-cinnamaldehyde on C. sakazakii adhesion and invasion of INT-407 cells. Results showed that 560 and 750 μM TC significantly inhibited adhesion (reduced by 35% and 47%, respectively) and invasion (750 μM completely inhibited invasion). PMC4057751
Streptococcus mutans UA159 156.25–5000 µg/mL 24 hours Trans-Cinnamaldehyde exhibited antibacterial effects on planktonic growth of S. mutans, with a minimal bactericidal concentration (MBC) of 2500 µg/mL. PMC10818508
Candida albicans ATCC 90028 0.5 mg/mL 24 hours Evaluate the inhibitory effect of pSi-TC on the growth of C. albicans, showing 97% inhibition at 0.5 mg/mL concentration. PMC9322055
Enterococcus faecalis biofilm cells 312.5, 625, 1250 μg/mL 24 hours To evaluate the bactericidal effect of the TC-ASL complex on Enterococcus faecalis biofilm cells. Results showed that TC-ASL significantly reduced the viable cell count of biofilms, and at concentrations of 312.5 and 625 μg/mL, TC-ASL was significantly more effective than TC alone. PMC9692797
MRSA DPS-3 250 µg/mL 24 hours To evaluate the synergistic antibacterial activity of TCA with eight conventional antibiotics, results showed that the MIC of antibiotics was reduced by 2-16-fold when combined with TCA. PMC7963149
MRSA DPS-1 250 µg/mL 24 hours To evaluate the synergistic antibacterial activity of TCA with eight conventional antibiotics, results showed that the MIC of antibiotics was reduced by 2-16-fold when combined with TCA. PMC7963149
Drug-resistant Klebsiella pneumoniae 512 µg/mL 24 hours Cinnamaldehyde in combination with ceftriaxone sodium showed synergistic inhibitory effects against drug-resistant Klebsiella pneumoniae. PMC10252610
Drug-resistant E. coli EBCC 256 µg/mL 24 hours Cinnamaldehyde in combination with ceftriaxone sodium showed synergistic inhibitory effects against drug-resistant E. coli. PMC10252610
Multidrug-resistant Salmonella SJ2 256 µg/mL 24 hours Cinnamaldehyde enhanced the antibacterial activity of ceftriaxone sodium against MDR Salmonella in vitro by significantly reducing the expression of extended-spectrum beta-lactamase, inhibiting the development of drug resistance under ceftriaxone selective pressure in vitro, damaging the cell membrane, and affecting its basic metabolism. PMC10252610
Primary human subcutaneous preadipocytes 40 µM 30 minutes To investigate the effect of trans-Cinnamaldehyde on Akt2 phosphorylation, results showed that trans-Cinnamaldehyde increased phosphorylation of Akt2 at T450 and Y475 sites, but had no effect on phosphorylation at S474 site. PMC9416494
K562 cells 120 or 180 μM 4, 9, or 24 hours TCA induced apoptosis in K562 cells by upregulating Fas expression and decreasing mitochondrial transmembrane potential, and enhanced the cytotoxicity of CIK cells against K562 cells. PMC4007726
Vero cells 0.38 mM 48 hours To evaluate the effect of trans-cinnamaldehyde on Clostridium difficile toxin-mediated cytotoxicity. Results showed that trans-cinnamaldehyde significantly reduced the cytotoxicity of C. difficile culture supernatant on Vero cells. PMC3975404

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice Autologous blood injection model Intraperitoneal injection 50 mg/kg Once daily for three days To evaluate the anti-inflammatory, antioxidant, anti-ferroptotic, and hematoma-limiting effects of trans-Cinnamaldehyde after intracerebral hemorrhage. Results showed that trans-Cinnamaldehyde has properties comparable to deferoxamine in these aspects. PMC11846400
C57BL/6 mice CORT- and CMS-induced depression models Intragastric gavage 10, 20, or 40 mg/kg Once daily for 6 weeks To evaluate the intervention effect of trans-cinnamaldehyde in depression model mice, results showed it prevented depressive-like phenotypes in F1 male offspring and ameliorated depressive-like behaviors in CVS-stimulated F1 offspring. PMC9343651
BALB/c nude mice Breast cancer xenograft model Intraperitoneal injection 100 mg/kg 56 days To evaluate the inhibitory effect of trans-cinnamaldehyde on visfatin-induced tumor proliferation, results showed that CA significantly inhibited tumor growth and proliferation-related protein expression PMC6943554
Mice 5XFAD transgenic mice Intraperitoneal injection 30 mg/kg Once daily for eight weeks To evaluate the effect of trans-cinnamaldehyde on Alzheimer's disease-related pathology, results showed that trans-cinnamaldehyde improved cognitive impairment and reduced Aβ deposition. PMC7352815
Sprague-Dawley rats Random flap model Oral gavage 10, 20, and 30 mg/kg Postoperative day 7 To investigate the effect of trans-cinnamaldehyde on skin flap survival and its possible mechanism regarding nitric oxide. Results showed that 20 mg/kg trans-cinnamaldehyde significantly increased flap survival and contributed to angiogenesis through the nitric oxide synthase pathway. PMC7899309

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

7.57mL

1.51mL

0.76mL

37.83mL

7.57mL

3.78mL

75.67mL

15.13mL

7.57mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories